GT Biopharma prices USD 7.75 million private placement of Series M preferred, warrants

• GT Biopharma expanded a private placement to raise USD 7.75 million through Series M 10% convertible preferred stock and accompanying warrants.
• Amendment increased issuance to 8,611 shares of preferred stock, up from 8,278, with warrants sized to the conversion shares.
• Purchasers received greenshoe rights for up to USD 31.21 million of additional preferred stock purchases, subject to adjustments.
• Transaction structured as an unregistered offering under Rule 506(b) of Regulation D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-043562), on September 21, 2026, and is solely responsible for the information contained therein.